Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8753

✍ Scribed by Case, Delvyn C. ;Santarelli, Maria Teresa ;Carey, Robert W. ;Anderson, James ;Gottlieb, Arlan

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 461 KB
• Volume: 20
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950200411

✦ Synopsis

Abstract

Ifosfamide (2.0 g/m^2^ intravenously/day × 3) with mesna (400 mg/m^2^ intravenously q 4 h daily × 3) was combined with mitoxantrone (14 mg/m^2^ intravenously × 1) and given on a 3 week schedule to patients with previously treated non‐Hodkgin's lymphoma. In 45 eligible/evaluable patients, a 47% response rate (95% confidence interval: 32%, 62%) was achieved of which 25% were complete responses and 22% were partial responses. Median duration of remission was 10 months with 42% of patients in remission at 18 months. Hematologic toxicity (granulocytopenia) was the dose‐limiting toxicity with severe or life‐threatening granulocytopenia in 98% of patients at full protocol doses. Nausea/vomiting was seen in 73% of patients but was usually mild/moderate. Three patients had significant hematuria secondary to ifosfamide. Two patients had severe changes in the left ventricular ejection fraction (LVEF) secondary to mitoxantrone; and one patient had acute neurologic dysfunction secondary to ifosfamide.

Ifosfamide/mesna can be safely combined with mitoxantrone at full doses in previously treated patients with non‐Hodkgin's lymphoma. This combination should be considered for other trials in lymphoma. © 1992 Wiley‐Liss, Inc.